Monitor the October 16 stockholder vote and any subsequent 8-K filings for closing conditions. The conference presentation (Oct 21-23) may generate pipeline-related news but is unlikely to move PULM shares materially before the merger vote.
Price Chart
Executive Summary
Eos SENOLYTIX announced its CEO will deliver a keynote at the 17th World Congress on Targeting Mitochondria (Oct 21-23, 2026) and reiterated that its merger with Pulmatrix is expected to close in Q4 2026, with a stockholder vote scheduled for October 16, 2026. The filing provides no new financial terms or deal changes, it is a routine conference and deal-status update.
Key Financial Metrics
Key Facts
- Eos CEO Kevin Slawin to deliver industry keynote at 17th World Congress on Targeting Mitochondria in Berlin, October 21-23, 2026.
- Eos lead candidate PTC-2105 is preclinical, targeting sarcopenia and sarcopenic obesity; IND-enabling studies ongoing.
- Pulmatrix stockholder special meeting scheduled for October 16, 2026 to vote on the merger.
- Merger anticipated to close in Q4 2026, subject to customary closing conditions.
- Combined company would trade under ticker MTXL.
- Merger-associated financings expected to support pipeline advancement, but no amounts disclosed.
Financial Impact
No financial figures disclosed; deal value, merger financing amounts, and PTC-2105 development costs not stated.
Risk Factors
- Merger may fail to obtain stockholder approval or satisfy closing conditions.
- PTC-2105 is preclinical; IND-enabling studies may fail to support first-in-human trials.
- Merger-associated financings may not be secured on favorable terms or at all.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001493152-26-043709 |
| Document: 0001493152-26-043709-index-headers.html | 0001493152-26-043709 |
| Document: 0001493152-26-043709-index.html | 0001493152-26-043709 |
| Document: 0001493152-26-043709.txt | 0001493152-26-043709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 30, 2026 today | 425 | $1.46 | awaiting T+5 | awaiting T+5 | $1.42 (−2.74%) |
Oct 23, 2026 7d ago | EFFECT | $1.48 | awaiting T+5 | awaiting T+5 | $1.42 (+4.05%) |
Oct 22, 2026 8d ago | 425 | $1.42 $1.41 | ▼ −0.70% | ▼ −1.41% | $1.42 (−0.00%) |
Oct 13, 2026 17d ago | 425 | $1.38 $1.43 | ▲ +3.62% | ▲ +4.77% | $1.42 (+2.90%) |
Oct 7, 2026 22d ago | DEFA14A | $1.53 $1.41 | ▼ −7.67% | ▼ −7.39% | $1.42 (−7.01%) |
Oct 2, 2026 27d ago | S-3/A | $1.48 $1.43 | ▲ +3.38% | ▲ +3.80% | $1.42 (+4.05%) |
Sep 28, 2026 4w ago | EFFECT | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.42 (+10.69%) |
Sep 25, 2026 4w ago | DEFM14A | $1.59 $1.48 | ▲ +6.92% | ▲ +8.12% | $1.42 (+10.69%) |
Sep 23, 2026 5w ago | S-4/A | $1.67 $1.54 | ▼ −7.78% | ▼ −7.37% | $1.42 (−14.97%) |
Sep 22, 2026 5w ago | 425 | $1.69 $1.52 | ▼ −9.79% | ▼ −9.12% | $1.42 (−15.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers